Multicenter, randomized and single-blind (group assigned by chance and unknown to study subjects), comparator-controlled study with all groups running in parallel to investigate the pharmacological effects, drug blood levels and safety of an intrauterine system releasing the study drug BAY 1007626 as compared to Mirena and Jaydess in healthy pre-menopausal women treated for 90 days to determine the study drug dose for further development Klinische Prüfung zur Bestimmung pharmakologischer Eigenschaften, der Wirkstoffkonzentration im Blut und der Sicherheit einer BAY1007626 freisetzenden Gebärmutterspirale im Vergleich mit Mirena und Jaydess bei gesunden, jungen Frauen über 90 Tage zur Bestimmung der Dosis für die weitere Arzneimittelentwicklung The primary objective of this study is to investigate local and systemic effects of BAY 1007626 on: – Number of bleeding and spotting days, – Endometrial histology, – Ovulation (as surrogate for sy...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multi-center, randomized, double blind, placebo controlled study to investigate the efficacy and safety of Aprotinin on transfusion requirements in patients with bladder cancer undergoing radical or total cystectomy Main objective: The objective of this study is to evaluate the safety and efficacy of aprotinin as compared to placebo, in reducing the need for subsequent blood transfusion in subjects with bladder c...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Quetiapine induced neuroplasticity in schizophrenic patients: A combined TMS and VBM study To evaluate the effect of treatment with quetiapine on aspects of structural neuroplasticity assessed by means of Voxel-based morphometry (changes in gray matter density baseline versus steady-state t...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Single-dose study testing rivaroxaban granules to be diluted into an oral suspension in children from 2 months to 12 years with previous blood clot To characterize the pharmacokinetic profile of rivaroxaban administered as granules for oral suspension

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to research BAY 1021189 in patients with worsening heart failure with preserved ejection fraction To find the optimal dose of BAY 1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment by characterizing the safety, tolerability, pharmacodynamic effects, ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Lipids in Diabetes Study Not provided at time of registration

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis The primary objective is to compare the change in FEV1 from baseline to Day 28-30 between Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH) To assess the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in treatment naive patients and patients pretreated with an Endothelin Receptor Antagonist or a Prostacyclin a...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to investigate the safety and efficacy of a six month oral treatment with a twice daily dose of BAY 1142524 in comparison to placebo in patients with reduced left-ventricular ejection fraction after acute myocardial infarction. Studie hodnotící bezpečnost a účinnost 6měsíční léčby přípravkem BAY 1142524 podávaného perorálně dvakrát denně, v porovnání s placebem, u pacientů se sníženou ejekční frakcí levé komory po akutním infarktu myokardu The primary objective of this study is to determine efficacy of BAY 1142524 by investigating the changes in LVEF, EDVI, and ESVI from baseline to 6 months after treatment with 25 mg of BAY 1142524 BID...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multi-center, open-label, randomized, controlled, parallel-group study to assess efficacy and safety of an extended flexible regimen of the combined oral contraceptive SH T00186D (0.02 mg ethinylestradiol as beta-cyclodextrin clathrate and 3 mg drospirenone) compared to the conventional regimen of SH T00186D in the treatment of primary dysmenorrhea To evaluate efficacy and safety of the combined oral contraceptive [COC] SH T00186D (0.02 mg ethinylestradiol [EE]; 3 mg drospirenone [DRSP]) applied in a conventional and an extended flexible regimen...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune